Transient FY26 For Syngene But Momentum In China +1 Projects

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Supply Chain
Syngene reaps gains of China +1 rebalancing (Shutterstock)

Syngene International navigated a tough fiscal 2025 and while wider global market dynamics remain uncertain, momentum in pharma’s China plus one supply chain network push and the recent acquisition of a biologics plant in the US are among the levers seen driving growth going forward.

Key Takeaways
  • Challenging FY25 for Syngene amid muted first half, driven by downturn in US biotech funding

Syngene’s managing director and CEO, Peter Bains, said that results for FY 2025 reflected a “resilient performance” in a challenging...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from India

More from Business